Archiv
Archiv anzeigen:
bis


Report from the 60th American Society of Hematology Annual Meeting

David Green, MD, PhD

Highlights of the latest research


The 2018 San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research


Genetic Testing for Breast Cancer: How Effective Are Guidelines?

Henry Mark Kuerer, MD, PhD, FACS reviewing Beitsch PD et al. J Clin Oncol 2018 Dec 7, Milliron KJ and Griggs JJ. J Clin Oncol 2018 Dec 7

National Comprehensive Cancer Network guidelines for multigene panel testing miss nearly half of patients with actionable variants.


NEJM Journal Watch Oncology and Hematology Top Stories of 2018

William J. Gradishar, MD

A perspective on the most important research in the field from the past year


Trifluridine/Tipiracil for Advanced Chemotherapy-Refractory Gastric Cancer

David H. Ilson, MD, PhD reviewing Shitara K et al. Lancet Oncol 2018 Nov 1

Overall survival was significantly longer with trifluridine/tipiracil than with placebo.


Ibrutinib as Initial Therapy for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Woyach JA et al. N Engl J Med 2018 Dec 1

Older patients with previously untreated disease had better outcomes with ibrutinib than with chemo-immunotherapy.


A New Complement Inhibitor for Paroxysmal Nocturnal Hemoglobinuria

David Green, MD, PhD reviewing Lee JW et al. Blood 2018 Dec 3, Kulasekararaj AG et al. Blood 2018 Dec 3

Ravulizumab was noninferior to eculizumab in both previously treated and treatment-naive patients.


CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Schuster SJ et al. N Engl J Med 2018 Dec 1

Forty percent of patients with relapsed or refractory disease achieved complete remission.


Utility of Radical Prostatectomy for Localized Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Bill-Axelson A et al. N Engl J Med 2018 Dec 13

At 23 years of follow-up, life expectancy was nearly 3 years longer with prostatectomy than with watchful waiting.


Thromboprophylaxis with Apixaban for Cancer Patients

David Green, MD, PhD reviewing Carrier M et al. N Engl J Med 2018 Dec 4

Venous thromboembolism occurred less frequently with the direct oral anticoagulant apixaban than with placebo.


Archiv
Seite von 76
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.